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RESEARCH ARTICLE
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To evaluate spinal radiographic damage over time and to explore the associations of radio-
graphic progression with patient characteristics and clinical assessments including disease
activity in ankylosing spondylitis (AS) patients treated with tumor necrosis factor-alpha
(TNF-α) blocking therapy in daily clinical practice.
Methods
Consecutive outpatients from the Groningen Leeuwarden AS (GLAS) cohort were included
based on the availability of cervical and lumbar radiographs before start of TNF-α blocking
therapy and after 2, 4, and/or 6 years of follow-up. Clinical data were assessed at the same
time points. Radiographs were scored by two independent readers using the modified
Stoke AS Spine Score (mSASSS). Spinal radiographic progression in relation to clinical as-
sessments was analyzed using generalized estimating equations.
Results
176 AS patients were included, 58% had syndesmophytes at baseline. Median mSASSS in-
creased significantly from 10.7 (IQR: 4.6–24.0) at baseline to 14.8 (IQR: 7.9–32.8) at 6
years. At the group level, spinal radiographic progression was linear with a mean progres-
sion rate of 1.3 mSASSS units per 2 years. Both spinal radiographic damage at baseline
and radiographic progression were highly variable between AS patients. Male gender, older
age, longer disease duration, higher BMI, longer smoking duration, high CRP, and high
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ASDAS were significantly associated with syndesmophytes at baseline. Significantly more
radiographic progression was seen in patients with versus without syndesmophytes (2.0 vs.
0.5 mSASSS units per 2 years) and in patients>40 versus40 years of age (1.8 vs. 0.7
mSASSS units per 2 years). No longitudinal associations between radiographic progression
and clinical assessments were found.
Conclusions
This prospective longitudinal observational cohort study in daily clinical practice shows
overall slow and linear spinal radiographic progression in AS patients treated with TNF-α
blocking therapy. At the individual level, progression was highly variable. Patients with syn-
desmophytes at baseline showed a 4-fold higher radiographic progression rate than pa-
tients without syndesmophytes.
Introduction
Ankylosing spondylitis (AS) is a chronic rheumatic inflammatory disorder which usually be-
gins before the fourth decade of life. AS is characterized by inflammation in combination with
new bone formation and bone loss. The disease mainly affects the axial skeleton and causes
pain, stiffness, and impaired functioning of the spine. The disease course is found to be highly
variable between AS patients. Excessive bone formation is an important disease outcome of AS.
In the spine, this comprises the formation of syndesmophytes which may lead to complete fu-
sion of the spine, resulting in a so-called ‘bamboo spine’. In most AS patients, it takes years
from the first disease symptoms to manifestations of bone formation on radiographs [1].
Therefore, long-term follow-up is needed to investigate radiographic progression.
Tumor necrosis factor-alpha (TNF-α) blocking therapy leads to a clear improvement in dis-
ease activity, functional outcome measures, and quality of life in the majority of AS patients
who do not respond to conventional treatment [1]. However, variable results have been re-
ported regarding the effect of TNF-α blocking therapy on the development of spinal radio-
graphic damage in AS. Multiple open-label extension studies did not show a significant
difference in spinal radiographic progression after 2 years of TNF-α blocking therapy com-
pared to TNF-α blocker naive AS patients from historical cohorts [2–5]. Two other open-label
extension studies could not demonstrate an inhibition of spinal radiographic progression dur-
ing 4 years of TNF-α blocking therapy [6,7]. However, in a retrospective study in only 22 AS
patients, diminished radiographic progression was found after 4 to 8 years of TNF-α blocking
therapy compared to AS patients from a historical cohort [8]. Furthermore, a large prospective
longitudinal observational study with 1.5 to 9 years of follow-up reported that TNF-α blocker
exposure (2.5 ± 2.8 years) was associated with less spinal radiographic progression [9].
These findings triggered the debate about the effect of TNF-α blocking therapy and the rela-
tionship between disease activity and spinal radiographic progression in AS. In previous cross-
sectional and longitudinal studies in AS patients with a large variability in disease duration, dis-
ease activity, and treatment regimens, disease activity at baseline and over time were associated
with spinal radiographic damage and progression [10–12]. Also, elevated inflammatory mark-
ers at baseline were found to be associated with the presence of syndesmophytes at baseline
and with radiographic progression in AS patients and in early axial spondyloarthritis (SpA)
[10,11]. Very recently, a longitudinal association between the AS Disease Activity Score
Spinal Radiographic Progression in AS
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(ASDAS) and radiographic progression was observed during 12 years of follow-up in a large
cohort of AS patients mainly treated with non-steroidal anti-inflammatory drugs (NSAIDs)
[12].
The aim of this prospective longitudinal cohort study was to evaluate spinal radiographic
damage over time and to explore the associations of radiographic progression with patient
characteristics and clinical assessments including disease activity in AS patients treated with
TNF-α blocking therapy in daily clinical practice.
Methods
The present analysis was based on data from the Groningen Leeuwarden Ankylosing Spondyli-
tis (GLAS) cohort. GLAS is an ongoing prospective longitudinal observational cohort study in
the northern part of the Netherlands. Since November 2004, this cohort included consecutive
AS outpatients who started TNF-α blocking therapy at the University Medical Center Gro-
ningen (UMCG) or the Medical Center Leeuwarden (MCL) because of active disease [13]. All
patients were over 18 years of age, fulfilled the modified New York criteria for AS [14], and the
ASAS criteria to start TNF-α blocking therapy (active disease defined as Bath AS Disease Activ-
ity Index (BASDAI) 4 and/or based on expert opinion) [15].
The choice of the TNF-α blocking agent (infliximab, etanercept, or adalimumab) was based
on the judgment of the treating rheumatologist and/or the specific preference of the patient. As
described previously, the standard regimen for infliximab was 5 mg/kg intravenously at 0, 2, 6
weeks and then every 8 weeks, for etanercept 50 mg (once) or 25 mg (twice) subcutaneous in-
jection every week, and for adalimumab 40 mg subcutaneous injection every two weeks [16].
Patients were clinically evaluated at baseline, after 3 months, and then every 6 months ac-
cording to a fixed protocol. Disease activity was measured at each follow-up visit and treatment
continuation was based on BASDAI improvement (50% or two units compared with base-
line) and/or expert opinion. Patients were allowed to switch between different TNF-α blocking
agents and to receive concomitant medication as usual in daily clinical practice. Type, dose,
and frequency of TNF-α blocking therapy were recorded at all follow-up visits. Temporary
stop was registered and the total duration of exposure to TNF-α blocking therapy was express-
ed as the percentage of follow-up time.
Patients included in the analysis started with TNF-α blocking therapy between 2004 and
October 2011 and had lateral radiographs of the cervical and lumbar spine available at baseline
and after at least 1 follow-up visit at 2, 4 and/or 6 years.
The GLAS cohort was approved by the local ethics committees of the MCL and the UMCG.
All patients provided written informed consent according to the Declaration of Helsinki.
Data collection
Baseline characteristics included: gender, age, symptom duration, time since diagnosis,
HLA-B27 status, history of smoking (duration in years), and history of extra-
articular manifestations.
At baseline and at each follow-up visit, disease activity was assessed with BASDAI [18],
ASDASCRP [19,20], physician’s and patient’s global assessment (GDA), C-reactive protein
(CRP), and erythrocyte sedimentation rate (ESR). Since all patients had high disease activity at
baseline and in order to analyze whether baseline disease activity status was associated with spi-
nal radiographic progression, cut-off values for very high disease activity as defined in previous
studies were used to stratify patients: BASDAI>6 [12], ASDAS>3.5 [21], physician’s and pa-
tient’s GDA>6 [21], CRP>10 mg/L, and ESR>20 mm/hr [11]. Furthermore, body weight
Spinal Radiographic Progression in AS
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and height were assessed to calculate body mass index (BMI), NSAID use was recorded, and
ASAS-NSAID index was calculated [17].
Assessments of spinal radiographic damage
Lateral radiographs of the cervical and lumbar spine were independently scored by two trained
readers (FM and RC). In order to blind readers for patient characteristics and time sequence,
all identifying information including exam dates were removed from the radiographs. Radio-
graphs were scored using the modified Stoke AS Spine Score (mSASSS). The anterior corners
of lower C2 until upper Th1 and lower Th12 until upper S1 were scored for the presence of ero-
sions, sclerosis, and/or squaring (1 point per vertebral site), non-bridging syndesmophytes (2
points per site), and bridging syndesmophytes (complete bridging of vertebrae; 3 points per
site). The mSASSS was calculated as the sum of the scores of all individual sites (range 0–72).
Patients with complete spinal ankylosis (mSASSS of 72) at baseline were excluded since no ra-
diographic progression could occur in these patients. If3 scores of vertebral sites were miss-
ing, the scores of these sites were substituted by the mean score of the vertebrae of the
corresponding spinal segment, as proposed by Wanders et al. [22,23]. If>3 scores of vertebral
sites were missing, the radiograph was excluded from the analysis. Radiographs were reassessed
if the mSASSS total score of both readers differed by>5 units. When the discrepancy of>5
units persisted after reassessment, consensus was reached. The average mSASSS total score of
both readers was used for the analysis.
Inter-observer reliability between readers for baseline mSASSS was very good, with an intra-
class correlation coefficient (ICC; two-way mixed effects model, single measures, absolute
agreement; before reassessment) of 0.987 (95% confidence interval (CI): 0.982–0.991). Inter-
observer reliability for mSASSS change scores was moderate to good with ICC’s of 0.690 (95%
CI: 0.596–0.765) for 0–2 year interval, 0.690 (95% CI: 0.545–0.794) for 2–4 year interval, and
0.400 (95% CI: 0.110–0.626) for 4–6 years interval. Bland-Altman plots revealed no systematic
error. The mean difference in progression scores between the two readers was 0.1 (95% CI -3.2
−3.4) for all 2-years intervals (S1 Fig).
Presence of syndesmophytes at baseline was defined when both readers scored a non-bridg-
ing or bridging syndesmophyte (2 points) at one or more vertebral sites. Inter-observer reli-
ability for presence of syndesmophytes was very good with Cohen’s kappa of 0.89 (95% CI 0.83
−0.96) and absolute agreement of 95%.
Definitions of spinal radiographic progression according to Baraliakos et al. were used to
distinguish between slow progression (<2 mSASSS units within 2 years), moderate progression
(2 to 5 mSASSS units within 2 years), and fast progression (>5 mSASSS units within 2 years)
[24].
Statistical analysis
Results were expressed as mean ± SD or median (interquartile range (IQR)) for normally dis-
tributed and non-normally distributed data, respectively. Independent samples T-test, Mann-
Whitney U test, Chi-Square test, and Fisher Exact test were used to compare differences in
baseline characteristics between groups.
Generalized estimating equations (GEE) was used to analyze spinal radiographic progres-
sion over time within subjects and to calculate mean radiographic progression rate at the group
level. Because correlations of spinal radiographic damage were approximately equal at different
time points, the exchangeable correlation structure was used. Different models of time (linear,
quadratic, cubic, square, logarithmic, and exponential) were used to investigate whether time
was linear or non-linear associated with radiographic progression. In case residuals were non-
Spinal Radiographic Progression in AS
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normally distributed, parameters were transformed (log or square root) before entered into
the equation.
In the baseline analysis, interactions between time and the following patient characteristics
and baseline clinical assessments were tested: gender, age, symptom duration, time since diag-
nosis, HLA-B27 status, BMI, duration of smoking, NSAID use, disease activity (BASDAI,
ASDAS, physician’s and patient’s GDA, CRP, ESR), and presence of syndesmophytes. If inter-
action effects with time were found (p-values0.05), the mean radiographic progression rate
was calculated after stratification into subgroups based on clinically relevant or median values.
In the longitudinal analysis, the relationship between radiographic progression and disease
activity, BMI, and NSAID use over time was investigated with an autoregressive marginal
time-lag model. This model investigates the influence of disease activity at the start of a 2-year
interval (eg. BASDAIt), BMI at the start of a 2-year interval (BMIt), or mean cumulative
NSAID use during a 2-year period (ASAS-NSAIDt−t+1) on the radiographic score at the end of
a 2-year interval (mSASSSt+1), adjusted for the radiographic score at the start of this interval
(mSASSSt) so radiographic progression was modeled. The following models were tested:
mSASSSt+1 modeled by mSASSSt and BASDAIt, ASDASt, physician’s GDAt, patient’s GDAt,
CRPt, ESRt. BMIt, and ASAS-NSAIDt−t+1,
Statistical analysis was performed with IBM SPSS Statistics 22 (SPSS, Chicago, IL, USA).
P values0.05 were considered statistically significant.
Results
In total, 176 of the 267 AS patients who started with TNF-α blocking therapy between Novem-
ber 2004 and October 2011 were included in the analysis (Fig 1). Baseline characteristics of in-
cluded patients were comparable to those who were excluded because of missing radiographs
(n = 78) or>3 missing vertebral edges (n = 5) at baseline or at follow-up, except for symptom
duration (median 14 vs. 17 years, p<0.05). Eight patients were excluded because of complete
spinal ankylosis at baseline. These patients were older (mean 55 vs. 42 years, p<0.01) and had
longer symptom duration (median 38 vs. 14 years, p<0.01).
Of the 176 included patients, 69% were male, mean age was 42 ± 11 years, median symptom
duration 14 years (IQR: 7–24), and 77% were HLA-B27 positive (Table 1). History of inflam-
matory bowel disease, uveitis, psoriasis, and peripheral arthritis were seen in 11%, 32%, 7%,
and 34% of the patients, respectively.
All patients had high disease activity at baseline (91% BASDAI4, 99% ASDAS2.1, and
68% CRP6mg/L). Twenty-seven (15%) patients started with infliximab, 110 (63%) with eta-
nercept, and 39 (22%) with adalimumab. During follow-up, 45 (26%) switched to another
TNF-α blocking agent. Patients were exposed to TNF-α blocking therapy for 97% of the fol-
low-up time (IQR: 83%- 100%).
Spinal radiographic damage and clinical assessments before the start of
TNF-α blocking therapy
At baseline, median mSASSS was 11 (IQR: 5–24) and 102 (58%) patients had at least one syn-
desmophyte according to both readers. Patients with syndesmophytes at baseline were more
frequently male, older, had longer symptom and diagnosis duration, higher BMI, longer dura-
tion of smoking, and had more often very high disease activity based on ASDAS (>3.5) and
CRP (>10 mg/L) (Table 1).
Spinal Radiographic Progression in AS
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Spinal radiographic progression during TNF-α blocking therapy and
baseline clinical assessments
Mean clinical follow-up time was 3.8 ± 1.8 years (range 1–7). During this period, 176, 151, 98,
and 50 patients had mSASSS data available at baseline and after 2, 4, and 6 years of follow-up,
respectively. Baseline characteristics were comparable in all these groups, only a significantly
longer symptom duration and higher ASAS-NSAID index were seen in patients with 6 years
data (Table 1 and S1 Table).
Median mSASSS increased significantly from 10.7 (IQR: 4.6–24.0) at baseline to 14.8 (IQR:
7.9–32.8) at 6 years (Table 2). At the group level, a linear time model revealed the best fit for
the data. Mean progression rate was estimated at 1.3 mSASSS units per 2 years.
At the individual level, both spinal radiographic damage at baseline and radiographic pro-
gression over time were highly variable between AS patients (Fig 2). During the 2-years inter-
vals, no or slow progression was found in 59–70%, moderate progression in 18–33%, and fast
progression in 5–12% of the patients (Table 2).
The presence of syndesmophytes and older age were significantly associated with spinal ra-
diographic progression. Patients with syndesmophytes at baseline had a 4-fold higher radio-
graphic progression rate than patients without syndesmophytes (2.0 vs. 0.5 mSASSS units per 2
years). This increased progression rate also applies for patients with only 1 syndesmophyte
compared to patients without syndesmophytes (1.8 vs. 0.5 mSASSS units per 2 years). Patients
>40 years of age showed a 2.5-fold higher radiographic progression rate than patients40
years (1.8 vs. 0.7 mSASSS units per 2 years) (Table 3).
Spinal radiographic progression and clinical assessments during TNF-α
blocking therapy
Disease activity improved significantly during TNF-α blocking therapy. From baseline to 3
months, mean BASDAI improved from 6.1 to 3.2, mean ASDAS from 3.7 to 2.1, median physi-
cian’s GDA from 4 to 2, median patient’s GDA from 7 to 3, median CRP from 12 to 3 mg/L,
and median ESR from 21 to 6 mm/hr (all p<0.001). These improvements remained stable
Fig 1. Flowchart of AS patients included in the analysis.
doi:10.1371/journal.pone.0122693.g001
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Table 1. Baseline characteristics of the total AS study population and stratified by the presence or absence of syndesmophytes at baseline.
Baseline syndemophytes
All patients (n = 176) Present (n = 102) Absent (n = 74) p-value
Male gender 121 (69) 78 (77) 43 (58) 0.009
Age (yrs) 42.3 ± 11.1 46.8 ± 10.1 36.2 ± 9.4 <0.001
Symptom duration (yrs) 14 (7–23) 18 (10–25) 10 (5–17) <0.001
Time since diagnosis (yrs) 5 (1–14) 8 (1–19) 3 (1–11) 0.011
HLA-B27+ 134 (77) 77 (76) 57 (77) 0.903
BMI (kg/m2) 26.4 ± 4.1 27.2 ± 4.1 25.2 ± 3.7 0.004
Smoking (yrs) 12 (0–22) 16 (0–25) 7 (0–16) 0.020
NSAID use 130 (74) 79 (78) 51 (69) 0.203
ASAS-NSAID index (0–100) 50 (0–100) 50 (0–100) 40 (0–100) 0.602
BASDAI (0–10) 6.1 ± 1.6 6.1 ± 1.5 6.0 ± 1.7 0.929
BASDAI >6 84 (48) 52 (51) 32 (43) 0.310
ASDASCRP 3.7 ± 0.8 3.8 ± 0.7 3.6 ± 0.8 0.150
ASDAS >3.5 104 (60) 68 (68) 36 (49) 0.013
Physician’s GDA (0–10) 4 (3–6) 4 (3–6) 4 (3–6) 0.701
Physician’s GDA >6 34 (20) 23 (23) 11 (16) 0.238
Patient’s GDA (0–10) 7 (5–8) 7 (5–8) 7 (6–8) 0.280
Patient’s GDA >6 105 (60) 56 (55) 49 (66) 0.151
CRP (mg/L) 12 (4–22) 14 (6–22) 9 (4–21) 0.141
CRP >10 mg/L 97 (56) 63 (62) 34 (47) 0.038
ESR (mm/hr) 21 (10–34) 20 (10–34) 21 (9–34) 0.832
ESR >20 mm/hr 87 (50) 49 (49) 38 (52) 0.691
mSASSS (range 0–72) 11 (5–24) 21 (12–38) 4 (2–7) <0.001
Values are presented as number of patients (%), mean ± SD, or median (IQR).AS: ankylosing spondylitis; HLA: human leukocyte antigen; BMI: body
mass index; NSAID: non-steroidal anti-inﬂammatory drug; ASAS: Assessment of SpondyloArthritis international Society; BASDAI: Bath AS Disease
Activity Index; ASDAS: AS Disease Activity Score; GDA: global disease activity; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; mSASSS:
modiﬁed Stoke AS Spine Score.
doi:10.1371/journal.pone.0122693.t001
Table 2. mSASSS status and progression scores of AS patients who started with TNF-α blocking therapy.
Status scores Baseline (n = 176) 2 year (n = 151) 4 year (n = 98) 6 year (n = 50)
Mean mSASSS 16.9 ± 16.7 17.5 ± 17.2 21.4 ± 18.5 21.4 ± 18.7
Median mSASSS 10.7 (4.6–24.0) 10.9 (4.6–25.5) 15.0 (5.6–32.1) 14.8 (7.9–32.8)
Progression scores 0–2 year (n = 151) 2–4 year (n = 75) 4–6 year (n = 42)
Mean change mSASSS 1.3 ± 3.2 1.4 ± 2.8 1.3 ± 2.0
Median change mSASSS 0.8 (-0.5–2.1) 1.2 (-0.6–2.8) 1.0 (-0.1–2.8)
<2 mSASSS units/2 years (slow) 106 (70) 44 (59) 27 (64)
2–5 mSASSS units/2 years (moderate) 27 (18) 25 (33) 13 (31)
>5 mSASSS units/2 years (fast) 18 (12) 6 (8) 2 (5)
Values are presented as number of patients (%), mean ± SD or median (IQR).
mSASSS: modiﬁed stoke AS spine score.
doi:10.1371/journal.pone.0122693.t002
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during long-term follow-up (data not shown). Mean BMI showed a small increase during fol-
low-up, from 26.4 at baseline to 26.6 at 6 years (p<0.05). NSAID use decreased significantly
from 74% at baseline to 41%, 37%, and 25% at 2, 4, and 6 years, respectively (p<0.001). Mean
cumulative NSAID intake according to the ASAS-NSAID index decreased from 24.3 during
the first 2 years to 14.4 and 9.2 during the 2–4 and 4–6 years time intervals, respectively
(p<0.001).
During TNF-α blocking therapy, no significant longitudinal associations were found be-
tween spinal radiographic progression and disease activity, BMI, or NSAID use over time
(Table 4). Also the change in disease activity during the first 3 to 6 months, remission at 6
months (e.g. ASDAS<1.3), prolonged remission (ASDAS<1.3 for at least 2 consecutive visits),
and change in NSAID use during the first 2 years were not significantly associated with spinal
radiographic progression (data not shown). Only a trend was observed for the longitudinal as-
sociation of CRP and ESR levels with radiographic progression (Table 4).
Discussion
This observational longitudinal cohort study prospectively investigated spinal radiographic
damage over time and the associations of radiographic progression with patient characteristics
Fig 2. Spinal radiographic progression at patient level of AS patients with 6 years of follow-up (n = 50).
doi:10.1371/journal.pone.0122693.g002
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and clinical assessments including disease activity in 176 AS patients treated with TNF-α
blocking therapy in daily clinical practice. Spinal radiographic progression was linear at the
group level with a mean progression rate of 1.3 mSASSS units per 2 years. This indicates that,
on average, AS patients treated with TNF-α blocking therapy showed slow radiographic pro-
gression according to the definitions of Baraliakos et al. (<2 mSASSS units per 2 years) [24].
Radiographic progression was also linear during 12 years of follow-up in a large cohort of AS
patients mainly treated with NSAIDs. In this cohort, the mean progression rate was estimated
Table 3. Effect of time and time interactions with baseline characteristics on spinal radiographic progression.
β (95% CI) p-value Intervals n
Time 1.25 (1.10–1.40) <0.001 475 176
Time*gender 0.104 475 176
Time*age 0.045 475 176
Age 40 years 0.68 (0.49–0.90) 206 75
Age >40 years 1.78 (1.64–1.93) 269 101
Time*symptom duration 0.565 448 166
Time*time since diagnosis 0.516 465 171
Time*HLA-B27 0.855 473 175
Time*BMI 0.221 360 141
Time*smoking 0.117 362 133
Time*NSAID use 0.246 475 176
Time*ASAS-NSAID index 0.668 381 130
Time*BASDAI 0.526 475 176
Time*ASDAS 0.764 467 173
Time*Physician’s GDA 0.123 466 172
Time*Patient’s GDA 0.506 473 175
Time*CRP 0.375 469 174
Time*ESR 0.339 466 173
Time*syndesmophytes 0.022 475 176
Without syndesmophytes 0.52 (0.39–0.66) 203 74
With syndesmophytes 2.02 (1.88–2.17) 272 102
See Table 1 for abbreviations.
doi:10.1371/journal.pone.0122693.t003
Table 4. Longitudinal analysis of the relationship between spinal radiographic progression and disease activity, BMI, and NSAID use.
β (95% CI) p-value Intervals n
Previous mSASSS 1.02 (1.00–1.04) <0.001 268 159
BASDAI -0.02 (-0.15–0.10) 0.737 259 159
ASDAS 0.24 (-0.08–0.55) 0.143 255 158
Physician’s GDA -0.05 (-0.19–0.09) 0.497 264 156
Patient’s GDA -0.03 (-0.16–0.10) 0.637 267 159
CRP 0.03 (0.00–0.06) 0.071 255 158
ESR 0.03 (0.00–0.06) 0.056 252 158
BMI -0.02 (-0.09–0.05) 0.596 266 181
ASAS-NSAID index 0.00 (-0.01–0.01) 0.905 196 87
See Table 1 for abbreviations.
doi:10.1371/journal.pone.0122693.t004
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at 2.0 mSASSS units per 2 years [12,25]. Although the mean 2-year progression rate found in
our patients treated with TNF-α blocking agents was lower, no conclusions can be made since
a direct comparison between the two cohorts is lacking. Other studies in AS patients treated
with TNF-α blocking therapy for 2–8 years showed variable mSASSS progression scores with a
minimum of 0.4 and a maximum of 1.8 mSASSS units per 2 years [2–8].
Before start of TNF-α blocking therapy, all AS patients had high disease activity and more
than half (58%) had syndesmophytes, which is comparable to the results of previous studies. In
these previous studies, the proportion of patients with syndesmophytes at baseline varied from
30% in ‘early’ AS (10 years symptom duration) [11], 47–58% in AS patients with a variable
disease activity status [25] to 55–61% in AS patients with active disease before start of TNF-α
blocking therapy [7,8]. In accordance with earlier findings, we found that male gender, older
age, elevated CRP levels, but also longer symptom and diagnosis duration, longer smoking du-
ration, and ASDAS>3.5 were significantly associated with the presence of syndesmophytes at
baseline [10,26]. Additionally, we found that patients with high disease activity and syndesmo-
phytes at baseline had significantly higher BMI which suggests an association between disease
activity, BMI, and radiographic damage. However, this could not be confirmed in the
longitudinal analyses.
At the individual level, spinal radiographic progression was highly variable. The mean
mSASSS progression rate was 4-fold higher in patients with syndesmophytes at baseline and
2.5-fold higher in patients>40 years of age. These findings indicate that radiographic progres-
sion during the treatment of TNF-α blocking therapy mainly occurs in older AS patients and
in patients with more advanced disease. Previous studies with different treatment regimens
also identified the presence of syndesmophytes at baseline as the most important predictor for
the development of more radiographic damage in both ‘early’ axial SpA [11] and longstanding
AS [2,10,24,27].
In our analyses, none of the disease activity assessments at baseline and over time were sig-
nificantly associated with spinal radiographic progression. This is probably due to the low vari-
ability in disease activity since all patients had high disease activity before start of TNF-α
blocking therapy and stable low disease activity during treatment. Moreover, the mean change
in mSASSS at the group level was small, which makes it difficult to observe significant differ-
ences. This was also confirmed by the low observed regression coefficients of the time-lagged
autoregressive GEE models. Historical longitudinal observational cohort studies in AS patients
that have found significant relationships between disease activity and radiographic progression
included patients with a high variability in disease activity status and treatment regimens
[11,12]. In the Outcome in AS International Study (OASIS), patients with very high disease ac-
tivity (ASDAS>3.5) over time showed an additional increase of 2.3 mSASSS unts per 2 years
compared to patients with inactive disease (ASDAS<1.3) [12]. In another analysis of the same
cohort, ESR was significantly associated with the development of new syndesmophytes after 4
years of follow-up (OR 1.03, 95% CI: 1.00–1.07, p<0.05) [10]. In 210 early axial SpA patients
from the German Spondyloarthritis Inception Cohort (GESPIC), elevated ESR levels at base-
line (>20 mm/hr) and time-averaged elevated CRP levels over 2 years (>6 mg/L) were signifi-
cantly associated with spinal radiographic progression during 2 years of follow-up [11].
Previous studies in AS reported a positive effect of continuous use of NSAIDs on the reduc-
tion of radiographic progression [28,29]. In our study, NSAID use decreased rapidly over time
resulting in very low ASAS-NSAID index scores, as expected in patients starting TNF-α block-
ing agents. Only 10% of the patients had a cumulative NSAID intake of50 according to the
ASAS-NSAID index and no effect on radiographic progression could be found. Furthermore,
follow-up data on smoking was not available in this study and therefore we could not include
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smoking in the longitudinal model to investigate this influence on spinal
radiographic progression.
In the present study the reading of the radiographs was done without known time sequence
which may lead to negative and smaller progression rates than when the reading was done in
chronological time order [30]. Furthermore, it was not possible to draw conclusions about the
effect of TNF-α blocking therapy on spinal radiographic progression, since AS patients without
TNF-α blocking therapy were not included.
Conclusion
This large prospective observational cohort study in AS patients treated with TNF-α blocking
therapy in daily clinical practice showed that spinal radiographic progression was overall slow
and linear at the group level. At the individual level, radiographic progression was highly vari-
able. Patients with syndesmophytes at baseline had a 4-fold increased radiographic progression
rate and patients>40 years of age had a 2.5-fold increased radiographic progression rate. No
longitudinal associations between radiographic progression and clinical assessments were
found. A direct longitudinal comparison between cohorts with long-term follow-up and large
study populations of AS patients treated with and without long-term TNF-α blocking therapy
is required to evaluate the effect of this treatment and to further investigate the relationship be-
tween clinical assessment (e.g. disease activity) and spinal radiographic progression.
Supporting Information
S1 Fig. Bland-Altman plot representing the reliability of the mSASSS change scores.
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